Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non–small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study
European Journal of Cancer2020Vol. 131, pp. 27–36
Citations Over TimeTop 10% of 2020 papers
Alexis B. Cortot, Clarisse Audigier-Valette, Olivier Molinier, Sylvestre Le Moulec, Fabrice Barlési, Gérard Zalcman, Patrick Dumont, Damien Pouessel, Claire Poulet, C. Fontaine-Delaruelle, Sandrine Hiret, A. Dixmier, P Renault, Catherine Becht, Olivier Raffy, C. Dayen, Julien Mazières, Éric Pichon, Alexandra Langlais, Franck Morin, Denis Moro‐Sibilot, Benjamin Besse
Related Papers
- → Effects of paclitaxel, docetaxel and their combinations on subcutaneous lymphomas in inbred Sprague–Dawley/Cub rats(2006)12 cited
- → Comparison of paclitaxel and docetaxel activity on human ovarian carcinoma xenografts(1994)34 cited
- → The scientific rationale for developing taxoids(1996)12 cited
- → Docetaxel as an Alternative to Paclitaxel after Acute Hypersensitivity Reactions(2000)33 cited
- → Surfactants influence the distribution of taxanes in peritoneal dissemination tumor-bearing rats(2009)6 cited